Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
ADVERTISEMENT
Tag Archive for: pipeline
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.